Menu
ncarol.com
  • Home
  • Books
  • Health
  • Book Release
  • Business
  • Manufacturing
  • Financial
  • Real Estate
  • Senior Living
ncarol.com

SafER has announced a Stage 3 clinical trial evaluating the SafER Negative Pressure System reducing aerosol emissions during bronchoscopic procedures
ncarol.com/10262631

Trending...
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
  • KeysCaribbean Resorts Offer Savings On Vacations Through Aug. 31, Preview Exceptional Select Fall Rates of Less Than $200/Night
Vacuum And Mask Respiratory Shield Endo Shield Hospital Nosuction 1 Hospital Suction 1c SafER Medical Products LLC
BRANSON, Mo. - ncarol.com -- Bronchoscopy is known to be an aerosol generating procedure and produce plumes of microscopic particles, some of which may carry infectious airborne organisms, that can then be inhaled by medical personnel in attendance and subsequently pose a high-risk of those medical staff contracting the disease.  "Our goal since the beginning of the pandemic has been to create a safer work environment for our friends and colleagues who are exposed to dangerous pathogens when performing aerosol generating procedures, while expanding access to those life-saving procedures for our patients", said SafER Chief Medical Officer, Dr. Rick Blubaugh.

The SafER system is the world's first portable negative pressure system that utilizes HEPA filtration to capture dangerous fugitive emissions at the source – the patient.  The system has been in use since the pandemic in hospitals, ambulances, and long-term facilities around the country and can be utilized during a variety of procedures including intubation, nebulizer, CPAP or Bi-Level PAP, endoscopy, and sputum or swab collection.

More on ncarol.com
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles

The study is randomized controlled and will take place in a 1,000-bed tertiary facility and is expected to enroll 80 patients over a 3-month period.  The goals of the study are to assess the system and the reduction of aerosol emissions produced during bronchoscopic procedures.  Results of the study are expected to be announced late this summer.

http://www.safermedicalproducts.com

Contact
Carl Baker
cbaker@safermedicalproducts.com


Source: SafER Medical Products LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • New Book Helps Educators Navigate AI in the Classroom While Keeping Humans in Charge
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • LifeTime Asset & Tax Management Named on the 2026 Inc. 5000 List
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • Pastor Miguel Bustillos Brings Deliverance and Exorcism Ministry Conference to Durham, NC
  • TOLI CORPORATION's President Visits U.S. to Celebrate Partnerships and Support North American Market
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
  • Priority Property Group Becomes Preferred Property Management Partner for Charlotte Investors
  • Inlow Upholstery Expands RV and Camper Upholstery Services in Western North Carolina
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
_catLbl0 _catLbl1

Popular on ncarol.com

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 228
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph - 126
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC) - 123
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 123
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home - 116
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care - 112
  • $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC) - 112
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services - 102
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings - 101
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering

Similar on ncarol.com

  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
  • Canadian Aerospace Defence Talent Expo (CADTE) Launches National TalentThread Initiative to Strengthen Canada's Future Workforce
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute